泰利克斯制药
TLX
10.69
+0.12
+1.14%
泰利克斯制药
US · TLX
#2345 按市值排名
上市于 2024
10.69
+0.12
+1.14%
实时 - 追踪5344个代码 - 心跳于393秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 机构持股总比例上升了0.9个百分点。
机构持股
- 机构持股比例
- 48.52% +0.93pp
- 机构数量
- 141
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund26.21%
Public Company15.59%
Individual/Insider14.84%
Government Pension Fund2.26%
Private Company1.50%
VC/PE Fund1.47%
Sovereign Wealth Fund1.35%
Hedge Fund0.14%
Other36.64%
主要股东 截至 2026-07-21
JPMorgan Chase & Co.
8.96% · 30.44M 股
State Street Global Advisors
8.06% · 27.38M 股
Andreas Kluge
6.67% · 22.68M 股
Christian Behrenbruch
6.41% · 21.80M 股
Challenger Limited
4.98% · 16.91M 股
Citigroup Inc.
3.35% · 11.39M 股
Grand Pharmaceutical Group Limited
3.22% · 10.95M 股
Vanguard Capital Management, LLC
3.13% · 10.62M 股
Australian Super
2.26% · 7.69M 股
Vanguard Investments Australia Limited
1.88% · 6.40M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪17份申报 · 3次买入 · 0次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Christian Behrenbruch | Co-Founder, MD, Group CEO & Executive Director | 6.41% |
| Mark Nelson | Independent Non-Executive Director | 1.07% |
| Jann Skinner | Independent Non-Executive Director | 0.18% |
| David Cade | Chief Executive Officer of Asia Pacific | 0.11% |
| Darren Patti | Chief Operating Officer of Americas | 0.01% |
| Darren Smith | Group Chief Financial Officer | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-06 | Darren Smith | Group Chief Financial Officer | Private Acquisition | +2,071 | $9.66 |
| 2026-04-28 | Christian Behrenbruch | Co-Founder, MD, Group CEO & Executive Director | Open Market Acquisition | +67,935 | $14.48–14.87 |
| 2026-03-28 | Darren Smith | Group Chief Financial Officer | Derivative Exercise and Retained | +1,111 | -- |
| 2026-03-17 | David Cade | Chief Executive Officer of Asia Pacific | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Darren Smith | Group Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Mark Nelson | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Christian Behrenbruch | Co-Founder, MD, Group CEO & Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Jann Skinner | Independent Non-Executive Director | Initial Statement of Beneficial | 0 | -- |
| 2026-03-17 | Darren Patti | Chief Operating Officer of Americas | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
泰利克斯制药 讨论区 0 条评论